Comparison

ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs BIOMARIN PHARMACEUTICAL INC (BMRN)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ALNY

ALNYLAM PHARMACEUTICALS, INC.

Biotechnology

Revenue, FY25: $3.71B
Net income: $314M
Operating cash flow: $524M
Free cash flow: $465M
Net margin: 8.45%
Operating margin: 13.51%
Gross margin: 81.77%

BMRN

BIOMARIN PHARMACEUTICAL INC

Biotechnology

Revenue, FY25: $3.22B
Net income: $349M
Operating cash flow: $828M
Free cash flow: $725M
Net margin: 10.83%
Operating margin: 12.71%
Gross margin: 77.73%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ALNY	BMRN
Revenue growth, latest filed year	+65.19%	+12.87%
Piotroski F-score	5 of 8	4 of 8
P/E against its own history	-	419.67% above

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ALNY

FDA approval
Reimbursement
Data privacy
Litigation
Tax
Product recalls

And 15 more.

BMRN

FDA approval
Data privacy
Reimbursement
Litigation
Tariffs
Debt covenants

And 15 more.

Tracked managers holding both

Dodge & Cox Dodge & Cox 0.31% · 0.44%
Joel Greenblatt Gotham Asset Management 0.03% · 0.00%

Updated Sep 1, 2026 · the newer of the two companies' filings